Mucin1 and Mucin16: Therapeutic Targets for Cancer Therapy

被引：58

作者：

Lee, Dong-Hee ^{[1
]}

Choi, Seunghyun ^{[2
]}

Park, Yoon ^{[2
]}

Jin, Hyung-seung ^{[1
]}

机构：

[1] Univ Ulsan, Asan Med Ctr, Asan Inst Life Sci, Dept Convergence Med,Coll Med, Seoul 05505, South Korea

[2] Korea Inst Sci & Technol KIST, Biomed Res Inst, Ctr Theragnosis, Seoul 02792, South Korea

来源：

PHARMACEUTICALS | 2021年 / 14卷 / 10期

基金：

新加坡国家研究基金会;

关键词：

mucin; MUC1; MUC16; immunotherapy; cancer vaccine; CAR (chimeric antigen receptor); ADC (antibody-drug conjugate); EPITHELIAL OVARIAN-CANCER; GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; CARCINOMA-ASSOCIATED ANTIGEN; MUC1; ONCOPROTEIN; MONOCLONAL-ANTIBODY; TUMOR-MARKER; CA; 125; IMMUNOLOGICAL RESPONSE; MAINTENANCE THERAPY;

D O I：

10.3390/ph14101053

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The mucin (MUC) family is a group of highly glycosylated macromolecules that are abundantly expressed in mammalian epithelial cells. MUC proteins contribute to the formation of the mucus barrier and thus have protective functions against infection. Interestingly, some MUC proteins are aberrantly expressed in cancer cells and are involved in cancer development and progression, including cell growth, proliferation, the inhibition of apoptosis, chemoresistance, metabolic reprogramming, and immune evasion. With their unique biological and structural features, MUC proteins have been considered promising therapeutic targets and also biomarkers for human cancer. In this review, we discuss the biological roles of the transmembrane mucins MUC1 and MUC16 in the context of hallmarks of cancer and current efforts to develop MUC1- and MUC16-targeted therapies.</p>

引用

页数：26

共 171 条

[61] Hallmarks of Cancer: The Next Generation [J].

Hanahan, Douglas ;

Weinberg, Robert A. .

CELL, 2011, 144 (05) :646-674

[62]

Hanaoka J, 2001, CANCER-AM CANCER SOC, V92, P2148, DOI 10.1002/1097-0142(20011015)92:8<2148::AID-CNCR1557>3.0.CO

[63]

2-6

[64] O-glycosylation of the mucin type [J].

Hanisch, FA .

BIOLOGICAL CHEMISTRY, 2001, 382 (02) :143-149

[65] MUC16: molecular analysis and its functional implications in benign and malignant conditions [J].

Haridas, Dhanya ;

Ponnusamy, Moorthy P. ;

Chugh, Seema ;

Lakshmanan, Imayavaramban ;

Seshacharyulu, Parthasarathy ;

Batra, Surinder K. .

FASEB JOURNAL, 2014, 28 (10) :4183-4199

[66] Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer [J].

Hata, Tsuyoshi ;

Rajabi, Hasan ;

Yamamoto, Masaaki ;

Jin, Caining ;

Ahmad, Rehan ;

Zhang, Yan ;

Kui, Ling ;

Li, Wei ;

Yasumizu, Yota ;

Hong, Deli ;

Miyo, Masaaki ;

Hiraki, Masayuki ;

Maeda, Takahiro ;

Suzuki, Yozo ;

Takahashi, Hidekazu ;

Samur, Mehmet ;

Kufe, Donald .

MOLECULAR CANCER THERAPEUTICS, 2019, 18 (10) :1744-1754

[67] USE OF A MURINE MONOCLONAL-ANTIBODY FOR DETECTION OF CIRCULATING PLASMA DF3 ANTIGEN LEVELS IN BREAST-CANCER PATIENTS [J].

HAYES, DF ;

SEKINE, H ;

OHNO, T ;

ABE, M ;

KEEFE, K ;

KUFE, DW .

JOURNAL OF CLINICAL INVESTIGATION, 1985, 75 (05) :1671-1678

[68] Mucins in cancer: Protection and control of the cell surface [J].

Hollingsworth, MA ;

Swanson, BJ .

NATURE REVIEWS CANCER, 2004, 4 (01) :45-60

[69] MUC1 cytoplasmic tail: a potential therapeutic target for ovarian carcinoma [J].

Hu, Xiu Feng ;

Yang, Eunice ;

Li, Jie ;

Xing, Pei Xiang .

EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) :1261-1271

[70] MUC1 oncoprotein blocks glycogen synthase kinase 3β-mediated phosphorylation and degradation of β-catenin [J].

Huang, L ;

Chen, DS ;

Liu, D ;

Yin, L ;

Kharbanda, S ;

Kufe, D .

CANCER RESEARCH, 2005, 65 (22) :10413-10422

← 2 3 4 5 6 7 8 9 10 11 →